Royal College of Obstetricians and Gynaecologists | 2010
Posted on

It is estimated that around 5% of the pregnant population (approximately 30 000 women per annum in the (UK) are offered a choice of invasive prenatal diagnostic tests (most commonly amniocentesis or chorionic villus sampling [CVS]). The type of diagnostic test available and offered is likely to vary depending upon the timing of any initial screening test that is performed. The aim of this guideline is to set a series of evidence-based standards to ensure a high level and consistency of practice in the provision and performance of amniocentesis and CVS. A systematic review was conducted of the standards and adverse effects of invasive prenatal diagnostic tests. The results of the review are summarized in 11 categories:

  • Rates of miscarriage associated with amniocentesis and CVS
  • At what gestation should amniocentesis and CVS be carried out?
  • What consent is required prior to performing amniocentesis or CVS?
  • What technique should be used to perform amniocentesis or CVS?
  • What is required for training and maintaining good practice in amniocentesis or CVS?
  • What are the clinical considerations when performing amniocentesis or CVS for multiple
  • pregnancy?
  • What information should women be given about third-trimester amniocentesis?
  • What are the risks of transmission of infection?
  • How should care be organised in providing amniocentesis and CVS?
  • Auditable standards
  • Areas for further research